NRXP Stock Risk & Deep Value Analysis
NRX Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on NRXP
We analyzed NRX Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran NRXP through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
NRXP Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About NRX Pharmaceuticals Inc (NRXP)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$75.59M
NRXP Deep Value Analysis
NRXP Red Flags & Warning Signs
- âš
Failure to secure sufficient non-dilutive funding, leading to further highly dilutive capital raises
- âš
Negative or inconclusive clinical trial results for NRX-101
- âš
Regulatory delays or rejection of NRX-101
- âš
Intensified competition in the broader depression treatment market
Unlock NRXP Red Flags & Risk Warnings
Create a free account to see the full analysis
NRXP Financial Health Metrics
Market Cap
$75.59M
NRXP Competitive Moat Analysis
Sign in to unlockMoat Rating
None
Moat Trend
Eroding (due to financial fragility that risks successful commercialization of IP) but has potential to expand upon successful product launch.
Moat Sources
1 Identified
The potential moat relies entirely on successful clinical development, regulatory approval, and crucially, the company's ability to secure adequate non-dilutive funding to bring NRX-101 to market. Without these, the inherent intellectual property value is at significant risk.
NRXP Competitive Moat Analysis
Sign up to see competitive advantages
NRXP Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated Early-May 2026)
- •Updates on NRX-101 Phase 3 trial enrollment and progress
Medium-Term (6-18 months)
- •Potential announcement of a strategic partnership for NRX-101 development/commercialization (6-18 months)
- •Interim data readout from NRX-101 Phase 3 trial (if applicable)
Long-Term (18+ months)
- •Topline data readout from NRX-101 Phase 3 trial (18-24+ months)
- •NRX-101 FDA approval and commercial launch
- •Establishment of market leadership in the Bipolar Depression with Suicidal Ideation segment
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
NRXP Bull Case: What Could Go Right
- ✓
Announcements of non-dilutive financing or significant strategic partnerships for NRX-101.
- ✓
Positive Phase 3 clinical trial data readout for NRX-101.
- ✓
Significant improvement in cash runway and reduction in burn rate.
- ✓
Insider buying activity indicating strong conviction from management.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
